McKendrick J J, Mead G M, Sweetenham J, Jones D H, Williams C J, Ryall R, Whitehouse J M
CRC Wessex Regional Medical Oncology Unit, University of Southampton, Hants, U.K.
Eur J Cancer Clin Oncol. 1989 Mar;25(3):557-61. doi: 10.1016/0277-5379(89)90270-8.
Between March 1978 and January 1987 54 patients with advanced Hodgkin's disease (HD) or relapse following radiotherapy (RT) for Hodgkin's disease have been treated with combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). A subgroup of five patients with bulky mediastinal disease received mantle RT in addition to ChlVPP chemotherapy. Forty-two patients (77.8%) entered complete remission with 33 (61.0%) remaining in unmaintained remission and 44 (81.5%) alive at a median follow up of 51 months (range: 22-103). The treatment was generally well tolerated with minimal toxicity. ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.
1978年3月至1987年1月期间，54例晚期霍奇金病（HD）患者或霍奇金病放疗（RT）后复发患者接受了由苯丁酸氮芥、长春花碱、丙卡巴肼和泼尼松龙（ChlVPP）组成的联合化疗。5例有巨大纵隔病变的患者亚组除接受ChlVPP化疗外还接受了斗篷野放疗。42例患者（77.8%）进入完全缓解期，33例（61.0%）维持未复发缓解状态，中位随访51个月（范围：22 - 103个月）时44例（81.5%）存活。该治疗总体耐受性良好，毒性极小。ChlVPP是霍奇金病有效的一线治疗方法，其疗效可能与MOPP相当，但毒性明显更低。
